Generate Biomedicines To Receive $30M Upfront, Up To $1.2B In Milestones And Tiered Royalties Under Zealand Pharma Collaboration

Generate Biomedicines Inc. has entered a strategic collaboration with Zealand Pharma A/S to develop multispecific protein therapeutics for obesity and metabolic diseases. The agreement includes an upfront payment of $30 million, with the potential for up to $1.2 billion in total milestones and tiered royalties on future sales. Generate will lead the research phase using its AI platform, while Zealand Pharma will handle clinical development and commercialization.